Related Experiment Videos
Diffuse large-cell lymphoma
1Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL, USA.
Background:
New treatments are desperately needed to improve the results obtained using CHOP chemotherapy for patients with diffuse large cell lymphoma. In order to develop successful new strategies we need to understand why prior promising therapies have failed and to develop new testable hypotheses based on our current knowledge.
Patients And Methods:
The International Non-Hodgkin's Lymphoma Prognostic Factors Index has provided us with a methodology to compare the expected prognosis of patients on different clinical trials. Many prior, apparent improvements in treatment outcome can now be attributed to the inclusion of patients with better prognoses.
Results:
Current areas of investigation include: 1) the identification of new active drugs for the treatment of lymphoma, 2) the use of colony stimulating factors to allow dose escalation of the active myelotoxic drugs, 3) the use of strategies which may overcome the problem of resistance to chemotherapy, 4) the combination of monoclonal antibodies with combination chemotherapy and 5) ablative chemotherapy with autologous stem-cell support.
Conclusions:
Based on all of the available data, the North American Lymphoma Intergroup has developed the hypothesis that high-intermediate and high risk patients with aggressive lymphoma who receive full course standard induction therapy will benefit form the addition of high dose therapy and has antedated a clinical trial testing that hypothesis.
Insights
New treatments are needed for diffuse large cell lymphoma. Research focuses on novel drugs, dose escalation, overcoming resistance, antibody combinations, and stem-cell support to improve patient outcomes.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Diffuse large cell lymphoma (DLCL) treatment outcomes require improvement.
- Understanding failures of prior therapies is crucial for developing new strategies.
Purpose of the Study:
- To explore novel therapeutic strategies for DLCL.
- To develop testable hypotheses for improving lymphoma treatment.
Main Methods:
- Utilizing the International Non-Hodgkin's Lymphoma Prognostic Factors Index for patient cohort comparison.
- Investigating new drug identification and dose escalation with colony-stimulating factors.
- Exploring strategies to overcome chemotherapy resistance and combining monoclonal antibodies with chemotherapy.
- Evaluating ablative chemotherapy with autologous stem-cell support.
Main Results:
- Current research areas include identifying new active drugs for lymphoma.
- Investigating dose escalation of myelotoxic drugs using colony-stimulating factors.
- Developing strategies to overcome chemotherapy resistance and combining monoclonal antibodies with chemotherapy.
- Assessing ablative chemotherapy with autologous stem-cell support.
Conclusions:
- A hypothesis suggests high-risk aggressive lymphoma patients benefit from high-dose therapy after standard induction.
- A clinical trial is planned to test this hypothesis for improved treatment outcomes.